John G. Houston, Ph.D. Entact Bio Appoints John G. Houston, Ph.D., to its Board of Directors A veteran biopharma innovator ...

As an added bonus, ProTac can be set to a "flicker mode" in which the PDLC continuously (and rapidly) switches back and forth between its transparent and opaque states. This allows the system to ...

Herein, as a proof of concept, we report a dual-mechanism degrader that can concurrently chemically induce the degradation of BTK and GSPT1 by merging the PROTAC and MG strategies. The representative ...

Researchers have developed an improved type of PROTAC that has enhanced intracellular accumulation and functions, not only as a degrader, but also as an inhibitor of the target protein. Cancer ...

PROTAC activates the cell's own protein disposal system. Credit: MPI of Molecular Physiology Most diseases are caused by proteins that have spun out of control. Unfortunately, so far, conventional ...

Dublin, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The "Global PROTAC Targeted Protein Degraders Market Opportunity & Clinical Trials Insight 2027" report has been added to ResearchAndMarkets.com's offering.

Figure 1: The crystal structure of the Brd4 BD2 –MZ1–VHL–ElonginC–ElonginB complex. We put forth a model for how cooperative recruitment of a target close to an E3 ligase in a ternary complex by a ...

An orally bioavailable androgen receptor PROTAC, developed using a protein degradation technology, was effective in lowering tumor burden in mice bearing human castration-resistant prostate cancer, ...

Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules that offer a promising therapeutic strategy against hard-to-treat diseases. Unlike traditional small molecule inhibitors, ...

The oncology market for PROTACs is projected to reach $3.7 billion by 2030, even though there are no FDA approved therapies currently. Protein homeostasis is critical for physiology of cell and their ...

Cancer therapies sometimes involve drugs that mediate the breakdown of specific intracellular proteins that participate in cancer formation and proliferation. Proteolysis-targeting chimeras or PROTACs ...

A promising strategy to reduce the impact of viral infectious diseases, such as influenza, is the use of attenuated, live viruses as vaccines. However, the usefulness of traditional live-attenuated ...